potassium tris(4-methyl-1-pyrazolyl)borohydride

KTp4-Me (potassium tris(4-methyl-1-pyrazolyl)borohydride) is a boron-pyrazole derivative that functions as an iron chelator with potential antineoplastic activity. It has been investigated primarily for the treatment of human hepatocellular carcinoma (HCC). By chelating ferrous iron, KTp4-Me disrupts cellular iron uptake and homeostasis, leading to a characteristic iron-deficiency response marked by the concentration-dependent induction of transferrin receptor 1 (TfR1) and hypoxia-inducible factor 1-alpha (HIF-1α). Preclinical studies in HCC cell lines, such as HepG2 and Hep3B, have demonstrated that the compound induces S-phase cell cycle arrest and triggers apoptosis, suggesting its potential as a lead molecule for the development of iron-targeted cancer therapies.

Other names

potassium tris(4-methyl-1H-pyrazol-1-yl)borohydride